Brian Mendelsohn

Brian Mendelsohn

Company: Ajinomoto Bio-Pharma Services

Job title: Director

Seminars:

ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform 9:20 am

Site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies We report a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner Both thiol-based and azide-based site-specific…Read more

day: Day Two

ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform 9:20 am

Site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies. We report a novel method of affinity peptide mediated regiodivergent antibody functionalization that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner. Both thiol-based and azide-based site-specific…Read more

Live Discussion & Question Time 10:00 am

Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.